Summary of the Conference Call Company and Industry Overview - The conference call involved **Site Sciences**, focusing on the **surgical glaucoma** and **dry eye** treatment markets, particularly the **minimally invasive glaucoma surgery (MIGS)** segment and the **TearCare** product for dry eye treatment [1][2][18]. Key Points on Surgical Glaucoma - **First Quarter Performance**: Surgical glaucoma revenue was initially guided to decline by 10-15% year-over-year but only decreased by 6%, indicating better-than-expected performance [2][26]. - **MIGS Environment**: The company is navigating a dynamic MIGS environment due to new restrictions limiting the combination of multiple MIGS procedures during cataract surgery, which has led to a decline in claims for these devices [3][4]. - **Product Performance**: Both **Omni** and **Scion** devices are performing slightly better than expected, with Omni's strong clinical efficacy and surgeon preference contributing to its market share [4][10]. - **Market Dynamics**: The transition to a one MIGS world is ongoing, with Omni positioned well due to its comprehensive functionality, allowing it to address multiple points of resistance in the outflow pathway [6][7]. - **Claims Data**: The volume of visits involving multiple MIGS procedures has dropped from 15% to 5%, indicating a significant shift in the market [11][12]. - **Long-term Growth Potential**: The market for MIGS is not fully penetrated, with significant opportunities in the combination cataract segment, as many patients undergoing cataract surgery are not receiving MIGS [18][19]. Key Points on Dry Eye Treatment - **TearCare Opportunity**: The company is focused on pioneering a new category of interventional dry eye treatment, addressing the underlying causes of dry eye disease, particularly obstructed meibomian glands [42][45]. - **Payer Discussions**: Productive conversations with payers are ongoing, with expectations for coverage policies and payment decisions to begin in 2025 [45][46]. - **Market Size**: There are over 19 million diagnosed patients with dry eye disease in the U.S., with a significant portion suffering from moderate to severe conditions, representing a large market opportunity [55][57]. - **Procedure Volume Potential**: The company estimates a potential for 7-8 million patients to undergo one or two procedures annually, depending on reimbursement rates [56][57]. - **Existing Infrastructure**: Site Sciences has a lean but experienced sales team ready to ramp up once reimbursement decisions are made, with over 1,500 trained smart hubs in place [49][50]. Additional Insights - **Competitive Landscape**: The introduction of new competitors, such as the Via 360 device, is acknowledged, but the company remains confident in the Omni product line and its ongoing innovations [31][34]. - **Market Education**: There is a need for continued education among surgeons regarding the importance of MIGS in the treatment paradigm to increase adoption rates [25][24]. - **Long-term Confidence**: The company expresses confidence in the long-term growth of both the MIGS and dry eye markets, emphasizing the importance of addressing unmet patient needs [20][21].

MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences’ management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a li ...

Financial Performance - For the quarter ended March 2025, Sight Sciences, Inc. reported revenue of $17.51 million, a decrease of 9.1% year-over-year [1] - The earnings per share (EPS) was -$0.28, an improvement from -$0.33 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $16.53 million by 5.95% [1] - The company delivered an EPS surprise of 3.45%, with the consensus EPS estimate being -$0.29 [1] Key Metrics - Revenue from Dry Eye was $0.39 million, surpassing the average estimate of $0.23 million, but reflecting a year-over-year decline of 60.9% [4] - Revenue from Surgical Glaucoma was $17.11 million, exceeding the estimated $16.23 million, but down 6.3% compared to the previous year [4] - Gross Profit for Dry Eye was $0.28 million, significantly higher than the two-analyst average estimate of $0.07 million [4] - Gross Profit for Surgical Glaucoma was $14.82 million, also above the estimated $14.09 million by two analysts [4] Stock Performance - Shares of Sight Sciences have returned +21.7% over the past month, outperforming the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 3.45%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.23, delivering a surprise of -15%.Over the last four quarters, the company has surpas ...

Sight Sciences Inc (SGHT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants None - ExecutivePaul Badawi - Founder, CEO & DirectorAli Bauerlein - CFOThomas Stephan - Vice PresidentMatt Link - CCOMacauley Kilbane - Equity Research Associate Conference Call Participants None - AnalystFrank Takkinen - Senior Research AnalystDavid Saxon - Senior Analyst Operator Good day, and thank you for standing by. Welcome to the SITE Sciences first quarter two thousand twenty five earning results conferenc ...

Sight Sciences Inc (SGHT) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SITE Sciences first quarter two thousand twenty five earning results conference call. At this time, all participants are in listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press 11 on your telephone. You would then hear an automated message advising your hand is raised ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 001-40587 Registrant's telephone number, including area code: (877) 266-1144 SIGHT SCIENCES, INC. N/A (Exact ...

Revenue for the first quarter of 2025 was $17.5 million, a decrease of 9% compared to the same period in the prior year. Surgical Glaucoma revenue was $17.1 million, a decrease of 6% compared to the same • Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's Surgical Glaucoma segment, which decreased 6% compared to the same period in the prior year. The expected decrease ...

Core Insights - Sight Sciences, Inc. reported a revenue of $17.5 million for Q1 2025, a 9% decrease compared to the same period in the previous year, primarily due to lower Surgical Glaucoma revenue and fewer Dry Eye product sales [4][7][10] - The company reaffirmed its revenue guidance for the full year 2025, expecting approximately $70.0 million to $75.0 million, reflecting a 6% to 12% decline compared to 2024 [10] - Adjusted operating expenses guidance for 2025 has improved, now expected to be approximately $101.0 million to $105.0 million, representing a 0% to 4% increase compared to 2024 [11] Financial Performance - Surgical Glaucoma revenue was $17.1 million, down 6% year-over-year, attributed to a 10% decrease in account utilization due to Medicare restrictions [4][10] - Dry Eye revenue decreased to $0.4 million from $1.0 million in the prior year, mainly due to a focus on reimbursed market access for TearCare [4][10] - Gross profit for Q1 2025 was $15.1 million, with a gross margin of 86%, unchanged from the previous year [5][7] Operating Expenses - Total operating expenses were $29.0 million, a 7% decrease from $31.2 million in the prior year, driven by lower legal expenses [6][7] - Research and development expenses were $4.4 million, down 4% year-over-year, while selling, general, and administrative expenses decreased by 8% to $24.5 million [6][7] Net Loss and Cash Position - The net loss for Q1 2025 was $14.2 million, or $0.28 per share, an improvement from a net loss of $16.3 million, or $0.33 per share, in the same period last year [8][29] - As of March 31, 2025, cash and cash equivalents totaled $108.8 million, down from $120.4 million at the end of 2024 [9][26] Strategic Initiatives - The company is focused on building commercial momentum in minimally invasive glaucoma surgery (MIGS) and establishing equitable reimbursement for TearCare, alongside advancing its product pipeline [3][10] - The recent launch of OMNI Edge at the ASCRS Annual Meeting is part of the company's strategy to enhance its product offerings [7][10]

Core Viewpoint - Sight Sciences, Inc. is set to report its financial results for Q1 2025 on May 8, 2025, with a conference call scheduled to discuss the results [1] Company Overview - Sight Sciences is an eyecare technology company focused on developing innovative interventional solutions to improve patient care and address prevalent eye diseases [3] - The company's OMNI® Surgical System is designed for glaucoma surgery, indicated for reducing intraocular pressure in adult patients with primary open-angle glaucoma [3] - The SION® Surgical Instrument is a bladeless device used in ophthalmic procedures to excise trabecular meshwork [3] - The TearCare® System is cleared for localized heat therapy in adult patients with evaporative dry eye disease, addressing meibomian gland disease [3]